CASI PharmaceuticalsFRA:ENM 29 Days Inventory is 54.34 as of Dec. 2025, which is 54% below its 10-year median of 117.54. GuruFocus rates FRA:ENM with a GF Score™ of 29/100 and a GF Value™ of €11.74. The stock has 5 warning signs investors should review. Among 635 Biotechnology companies, CASI Pharmaceuticals ranks better than 67.09% on this metric.
The historical rank and industry rank for CASI Pharmaceuticals's Days Inventory or its related term are showing as below:
FRA:ENM'
s Days Inventory Range Over the Past 10 Years
Min: 47.42 Med: 117.54 Max: 290.57
Current: 116.75
During the past 13 years, CASI Pharmaceuticals's highest Days Inventory was 290.57. The lowest was 47.42. And the median was 117.54.
FRA:ENM's Days Inventory is ranked better than 67.09% of 635
companies
in the Biotechnology industry
Industry Median: 183.23
vs FRA:ENM: 116.75
CASI Pharmaceuticals's Days Inventory
declined
from Dec. 2024 (78.59) to Dec. 2025 (54.34).
Inventory Turnover measures how fast the company turns over its inventory within a year.
CASI Pharmaceuticals's Inventory Turnover for the
three
months ended in Dec. 2025 was 1.68.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
CASI Pharmaceuticals's Inventory-to-Revenue for the
three
months ended in Dec. 2025 was 0.29.
CASI Pharmaceuticals (FRA:ENM) Days Inventory Explanation
Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:
1. Inventory Turnover measures how fast the company turns over its inventory within a year.
CASI Pharmaceuticals's Inventory Turnover for the
three
months ended in Dec. 2025 is calculated as
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
CASI Pharmaceuticals's Inventory to Revenue for the
three
months ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.
CASI Pharmaceuticals Days Inventory Related Terms
CASI Pharmaceuticals Days Inventory Historical Data
* Premium members only.
The historical data trend for CASI Pharmaceuticals's Days Inventory can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:ENM vs ITRMF, OGEN, AZTR: Days Inventory Comparison
For the Biotechnology subindustry, CASI Pharmaceuticals's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CASI Pharmaceuticals Days Inventory vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, CASI Pharmaceuticals's Days Inventory distribution charts can be found below:
* The bar in red indicates where CASI Pharmaceuticals's Days Inventory falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CASI Pharmaceuticals (FRA:ENM) has a Days Inventory of 54.34 as of Dec. 2025. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on CASI Pharmaceuticals and its competitors. This is 54% below median its historical median of 117.54. Over the past decade, CASI Pharmaceuticals' Days Inventory has ranged from 47.42 to 290.57. According to the industry distribution chart, CASI Pharmaceuticals ranks #209 out of 635 companies in the Biotechnology industry, placing it in the top 32.9%.
Is CASI Pharmaceuticals' Days Inventory too high?
CASI Pharmaceuticals' current Days Inventory of 54.34 is 54% below median its 10-year median of 117.54. Over the past 10 years, this metric has ranged from a low of 47.42 to a high of 290.57. The Biotechnology industry median Days Inventory is 183.23. CASI Pharmaceuticals' value of 54.34 is 70.3% below this industry median. Based on the distribution chart, CASI Pharmaceuticals ranks #209 out of 635 companies in the Biotechnology industry, which is above the industry midpoint. Overall, CASI Pharmaceuticals has a GF Score™ of 29/100, reflecting its overall financial health beyond just this single metric.
How does CASI Pharmaceuticals' Days Inventory compare to ITRMF and OGEN?
According to the Biotechnology industry distribution chart, CASI Pharmaceuticals ranks #209 out of 635 companies for Days Inventory. This puts CASI Pharmaceuticals in the upper half of its industry. The industry median Days Inventory is 183.23. CASI Pharmaceuticals' value of 54.34 is 70.3% below this benchmark. Historically, CASI Pharmaceuticals' own Days Inventory has ranged from 47.42 to 290.57 over the past decade. While the company's 10-year median is 117.54 vs. the industry median of 183.23, CASI Pharmaceuticals has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Inventory for a Biotechnology company?
The median Days Inventory among Biotechnology companies is 183.23, based on 635 companies in the industry. Companies in the top quartile (top 25%) have a Days Inventory significantly above this median, while those in the bottom quartile fall well below. However, Days Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. CASI Pharmaceuticals's current Days Inventory of 54.34 is 70.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Inventory mean?
A high Days Inventory can signal that a stock is expensive relative to its fundamentals. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on CASI Pharmaceuticals and its competitors. For the Biotechnology industry, the median Days Inventory is 183.23 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CASI Pharmaceuticals's current Days Inventory is 54.34, which is 54% below median its own 10-year median of 117.54. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CASI Pharmaceuticals stock overvalued right now?
CASI Pharmaceuticals (FRA:ENM) has a current Days Inventory of 54.34. The stock's GF Value™ is €11.74, compared to a current price of €1.54 — trading 86.9% below its estimated fair value. The current Days Inventory is 54.34, which is 54% below median its 10-year median of 117.54 and 70.3% below the Biotechnology industry median of 183.23. CASI Pharmaceuticals' overall GF Score™ is 29/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Inventory calculated?
Days Inventory is calculated from a company's financial statements. For CASI Pharmaceuticals (FRA:ENM), the current Days Inventory is 54.34 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is CASI Pharmaceuticals (FRA:ENM) Overvalued in 2026?
Based on GuruFocus' analysis, CASI Pharmaceuticals stock appears to be undervalued.
The current stock price of €1.54 is trading 86.9% below its estimated GF Value™ of €11.74.
Key valuation signals for FRA:ENM:
Days Inventory: 54.34 (54% below median its 10-year median of 117.54)
GF Value™: €11.74 vs. price of €1.54 (86.9% below fair value)
Industry Position: 70.3% below the Biotechnology median (#209 of 635)
No single metric tells the full story. See the FRA:ENM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
CASI Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing CID-103, an anti-CD38 monoclonal antibody, for patients with organ transplant rejection and autoimmune diseases. Additionally, the company manages its other assets, including EVOMELA, FOLOTYN, CNCT19, BI-1206, and CB-5339, with a primary strategic emphasis on advancing CID-103 toward key clinical and regulatory milestones. It also distributes YuTuo (Zimberelimab), a fully human anti-PD-1 monoclonal antibody for patients with relapsed or refractory classical Hodgkin's lymphoma and recurrent or metastatic cervical cancer. Geographically, the company's revenue is solely generated in Mainland China.
29GF Score
Get the complete analysis for FRA:ENM
Days Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:ENM has been successfully added to your 
